SecBot SecBot
Biotech Drug Report Generated Oct 29, 2026

VARIVAX

MRK·Merck & Co., Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and commercially marketed since 1995.
Why 3/10
No hard, dated catalyst (PDUFA, pivotal readout, AdComm) is scheduled for VARIVAX in the next ~12 months. It is an already-approved, marketed vaccine with no pending regulatory decision, which per the rubric caps the impact score at 3-5. It is also a very small component of Merck's $65B+ revenue base.
Actionable Insight NEUTRAL

VARIVAX has no upcoming PDUFA date, pivotal readout, or other hard binary catalyst. As a mature, approved vaccine in Merck's broad portfolio, its commercial performance will be reported as part of Merck's quarterly vaccine segment results, but it is unlikely to drive meaningful share-price movement on its own. Investors should watch for any competitive entries or CDC immunization schedule changes that could affect the varicella vaccine market.

Price Chart

Loading chart...

Executive Summary

VARIVAX is Merck's live attenuated varicella (chickenpox) vaccine, FDA-approved since March 1995 and the only standalone varicella vaccine available in the U.S. It is a mature, commercially marketed product with no pending regulatory catalysts. Merck is the sole U.S. manufacturer of varicella vaccine (both standalone VARIVAX and combination MMRV vaccine ProQuad). The combined ProQuad/M-M-R II/Varivax franchise generated roughly $538 million in 2026, a small fraction of Merck's $65B+ total revenue. The drug's prescribing information was updated in August 2026, but no near-term binary catalysts exist for this product.

How It Works

VARIVAX is a live, weakened (attenuated) form of the varicella-zoster virus, the virus that causes chickenpox. When injected, it triggers the immune system to produce antibodies and memory cells that protect against future chickenpox infection, without causing the disease itself in healthy people.

Trial Status

VARIVAX was FDA-approved in March 1995 and has been commercially marketed for over 30 years. It is indicated for active immunization against varicella (chickenpox) in individuals 12 months of age and older. The vaccine is administered as a two-dose regimen. Merck updated the prescribing information most recently in August 2026.

The Two-Sided Case

▲ Bull Case4
Merck is the sole U.S. manufacturer of varicella vaccine (VARIVAX and ProQuad), giving it a captive market with no direct domestic competitor.
The global varicella vaccine market is projected to grow at a CAGR of roughly 5-6% through 2035, driven by expanding immunization programs in emerging economies.
VARIVAX has been on the market for over 30 years with an established safety and efficacy profile, making it a stable, low-risk revenue contributor.
The prescribing information update in August 2026 reflects ongoing lifecycle management and regulatory compliance.
▼ Bear Case5
VARIVAX is a very small part of Merck's business: the combined ProQuad/M-M-R II/Varivax franchise generated roughly $538 million in 2026, less than 1% of Merck's $65B+ total revenue, so its performance has negligible impact on the stock.
The vaccine market faces pricing pressure and potential shifts in CDC immunization schedules that could affect volumes.
Global competitors such as GSK, GC Pharma, and others offer varicella vaccines in markets outside the U.S., limiting international pricing power.
As a live attenuated vaccine, VARIVAX has contraindications for immunocompromised individuals and pregnant women, limiting its addressable population.
Patent and regulatory exclusivity protections for a 1995-approved product are largely expired, though manufacturing complexity provides a barrier to entry.

Upcoming Catalysts

  • None scheduled for VARIVAX specifically. Merck's quarterly earnings reports will include vaccine segment performance.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Merck & Co., Inc. 8-K MRK ·Originating report

Sources · 10

Hover a chip for the title
1 fda.gov2 merckvaccines.com3 merck.com4 geneonline.com5 fiscal.ai6 merck.com7 sec.gov8 mordorintelligence.com9 gminsights.com10 stocklight.com